- Home
- RSG vs REGN Comparison
RSG vs REGN Comparison
Compare RSG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSG
- REGN
- Stock Information
- Founded
- RSG 1996
- REGN 1988
- Country
- RSG United States
- REGN United States
- Employees
- RSG N/A
- REGN N/A
- Industry
- RSG Environmental Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- RSG Utilities
- REGN Health Care
- Exchange
- RSG Nasdaq
- REGN Nasdaq
- Market Cap
- RSG 76.2B
- REGN 63.4B
- IPO Year
- RSG 1998
- REGN 1991
- Fundamental
- Price
- RSG $243.28
- REGN $563.16
- Analyst Decision
- RSG Buy
- REGN Buy
- Analyst Count
- RSG 18
- REGN 23
- Target Price
- RSG $235.18
- REGN $971.57
- AVG Volume (30 Days)
- RSG 1.7M
- REGN 1.1M
- Earning Date
- RSG 04-24-2025
- REGN 04-29-2025
- Dividend Yield
- RSG 0.95%
- REGN 0.16%
- EPS Growth
- RSG 18.65
- REGN 10.27
- EPS
- RSG 6.49
- REGN 38.34
- Revenue
- RSG $16,032,000,000.00
- REGN $14,202,000,000.00
- Revenue This Year
- RSG $6.38
- REGN $4.06
- Revenue Next Year
- RSG $5.22
- REGN $6.54
- P/E Ratio
- RSG $37.49
- REGN $14.69
- Revenue Growth
- RSG 7.13
- REGN 8.27
- 52 Week Low
- RSG $180.92
- REGN $525.99
- 52 Week High
- RSG $249.73
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- RSG 56.89
- REGN 37.15
- Support Level
- RSG $242.30
- REGN $544.50
- Resistance Level
- RSG $247.24
- REGN $575.20
- Average True Range (ATR)
- RSG 7.19
- REGN 28.44
- MACD
- RSG 0.19
- REGN -1.59
- Stochastic Oscillator
- RSG 74.80
- REGN 32.25
About RSG Republic Services Inc.
Republic Services is the second-largest integrated provider of traditional solid waste services in the United States, operating roughly 207 active landfills and 246 transfer stations. The company serves residential, commercial, and industrial end markets. It also runs a sizable recycling operation in North America.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).